ID   OVCA420
AC   CVCL_3935
SY   OVCA 420; OvCa 420; OVCA-420; OVCAR-420; OVCAR 420; OVCAR420
DR   BTO; BTO:0002563
DR   EFO; EFO_0006720
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03471874
DR   CCLE; OVCA420_OVARY
DR   Cell_Model_Passport; SIDM00967
DR   Cosmic; 924145
DR   Cosmic; 927566
DR   Cosmic-CLP; 1480364
DR   DepMap; ACH-002181
DR   GDSC; 1480364
DR   GEO; GSM659390
DR   GEO; GSM711703
DR   GEO; GSM851928
DR   GEO; GSM1340585
DR   GEO; GSM1341130
DR   GEO; GSM1670315
DR   GEO; GSM2474990
DR   IARC_TP53; 28490
DR   PharmacoDB; OVCA420_1213_2019
DR   Wikidata; Q54936981
RX   PubMed=1536252;
RX   PubMed=6346879;
RX   PubMed=7028788;
RX   PubMed=10318951;
RX   PubMed=10972993;
RX   PubMed=11793438;
RX   PubMed=12960427;
RX   PubMed=22115851;
RX   PubMed=22710073;
RX   PubMed=23415752;
RX   PubMed=25485619;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=28273451;
RX   PubMed=30894373;
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   Doubling time: 47.62 hours (https://www.synapse.org/#!Synapse:syn2347014).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (PubMed=28273451).
CC   Omics: Deep exome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=82.47%; Native American=0%; East Asian, North=2.6%; East Asian, South=0%; South Asian=2.8%; European, North=3.32%; European, South=8.81% (PubMed=30894373).
CC   Derived from sampling site: Ovary.
ST   Source(s): Cosmic-CLP; PubMed=22115851; PubMed=22710073; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 8
ST   D13S317: 12,13
ST   D16S539: 9 (PubMed=22115851; PubMed=22710073)
ST   D16S539: 9,12 (Cosmic-CLP; PubMed=25877200)
ST   D18S51: 14,17
ST   D19S433: 11,15.2
ST   D21S11: 30.2
ST   D2S1338: 19,22
ST   D3S1358: 16,17
ST   D5S818: 13
ST   D7S820: 8,11 (PubMed=25877200)
ST   D7S820: 11 (Cosmic-CLP; PubMed=22115851; PubMed=22710073)
ST   D8S1179: 14,15
ST   FGA: 22 (PubMed=22115851; PubMed=22710073)
ST   FGA: 21,22 (PubMed=25877200)
ST   Penta D: 12
ST   Penta E: 5,8
ST   TH01: 6 (PubMed=22710073; PubMed=25877200)
ST   TH01: 6,9 (Cosmic-CLP)
ST   TPOX: 8
ST   vWA: 16,18
DI   NCIt; C7550; Ovarian serous adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 20-05-21; Version: 25
//
RX   PubMed=1536252; DOI=10.1016/0002-9378(92)91697-9;
RA   Berchuck A., Rodriguez G., Olt G., Whitaker R., Boente M.P.,
RA   Arrick B.A., Clarke-Pearson D.L., Bast R.C. Jr.;
RT   "Regulation of growth of normal ovarian epithelial cells and ovarian
RT   cancer cell lines by transforming growth factor-beta.";
RL   Am. J. Obstet. Gynecol. 166:676-684(1992).
//
RX   PubMed=6346879; DOI=10.1016/0002-9378(83)90999-7;
RA   Berkowitz R., Kabawat S., Lazarus H., Colvin R.B., Knapp R.C.,
RA   Bast R.C. Jr.;
RT   "Comparison of a rabbit heteroantiserum and a murine monoclonal
RT   antibody raised against a human epithelial ovarian carcinoma cell
RT   line.";
RL   Am. J. Obstet. Gynecol. 146:607-612(1983).
//
RX   PubMed=7028788; DOI=10.1172/JCI110380;
RA   Bast R.C. Jr., Feeney M., Lazarus H., Nadler L.M., Colvin R.B.,
RA   Knapp R.C.;
RT   "Reactivity of a monoclonal antibody with human ovarian carcinoma.";
RL   J. Clin. Invest. 68:1331-1337(1981).
//
RX   PubMed=10318951; DOI=10.1073/pnas.96.10.5722;
RA   Lau K.-M., Mok S.C., Ho S.-M.;
RT   "Expression of human estrogen receptor-alpha and -beta, progesterone
RT   receptor, and androgen receptor mRNA in normal and malignant ovarian
RT   epithelial cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:5722-5727(1999).
//
RX   PubMed=10972993; DOI=10.1002/1098-2744(200008)28:4<236::AID-MC6>3.0.CO;2-H;
RA   Rauh-Adelmann C., Lau K.-M., Sabeti N., Long J.P., Mok S.C., Ho S.-M.;
RT   "Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon
RT   12 deletion variant in malignant human ovarian, prostate, and breast
RT   cancer cell lines.";
RL   Mol. Carcinog. 28:236-246(2000).
//
RX   PubMed=11793438; DOI=10.1002/gcc.1221;
RA   Rao P.H., Harris C.P., Lu X.-Y., Li X.-N., Mok S.C., Lau C.C.;
RT   "Multicolor spectral karyotyping of serous ovarian adenocarcinoma.";
RL   Genes Chromosomes Cancer 33:123-132(2002).
//
RX   PubMed=12960427; DOI=10.1091/mbc.E03-05-0279;
RA   Schaner M.E., Ross D.T., Ciaravino G., Sorlie T., Troyanskaya O.,
RA   Diehn M., Wang Y.C., Duran G.E., Sikic T.L., Caldeira S., Skomedal H.,
RA   Tu I.-P., Hernandez-Boussard T., Johnson S.W., O'Dwyer P.J., Fero M.J.,
RA   Kristensen G.B., Borresen-Dale A.-L., Hastie T., Tibshirani R.,
RA   van de Rijn M., Teng N.N.H., Longacre T.A., Botstein D., Brown P.O.,
RA   Sikic B.I.;
RT   "Gene expression patterns in ovarian carcinomas.";
RL   Mol. Biol. Cell 14:4376-4386(2003).
//
RX   PubMed=22115851; DOI=10.1016/j.ygyno.2011.11.019;
RA   Vishnu P., Colon-Otero G., Kennedy G.T., Marlow L.A., Kennedy W.P.,
RA   Wu K.J., Santoso J.T., Copland J.A.;
RT   "RhoB mediates antitumor synergy of combined ixabepilone and sunitinib
RT   in human ovarian serous cancer.";
RL   Gynecol. Oncol. 124:589-597(2012).
//
RX   PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017;
RA   Korch C., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K.,
RA   Lessey B.A., Jordan V.C., Bradford A.P.;
RT   "DNA profiling analysis of endometrial and ovarian cell lines reveals
RT   misidentification, redundancy and contamination.";
RL   Gynecol. Oncol. 127:241-248(2012).
//
RX   PubMed=23415752; DOI=10.1016/j.molonc.2012.12.007;
RA   Stordal B., Timms K., Farrelly A., Gallagher D., Busschots S.,
RA   Renaud M., Thery J., Williams D., Potter J., Tran T., Korpanty G.,
RA   Cremona M., Carey M.S., Li J., Li Y., Aslan O., O'Leary J.J.,
RA   Mills G.B., Hennessy B.T.;
RT   "BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one
RT   functionally deleterious BRCA1 mutation.";
RL   Mol. Oncol. 7:567-579(2013).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=28273451; DOI=10.1016/j.celrep.2017.02.028;
RA   Medrano M., Communal L., Brown K.R., Iwanicki M., Normand J.,
RA   Paterson J., Sircoulomb F., Krzyzanowski P., Novak M., Doodnauth S.A.,
RA   Saiz F.S., Cullis J., Al-Awar R., Neel B.G., McPherson J., Drapkin R.,
RA   Ailles L., Mes-Masson A.-M., Rottapel R.;
RT   "Interrogation of functional cell-surface markers identifies CD151
RT   dependency in high-grade serous ovarian cancer.";
RL   Cell Rep. 18:2343-2358(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//